Latest data from January 14, 2022
Number of Health Center respondents = 3 (100% of all Health Centers)
Data represents information provided by health centers from a single, specified reporting date. Summary information across report dates is not comparable due to differences in which health centers responded for a given report date.
Patients Tested
| Metrics | Value |
|---|---|
| Patients Tested for COVID-19, Virus Detection (PCR, Antigen)1 | 619 |
| Racial and/or Ethnic Minority Patients Tested for COVID-19, Virus Detection (PCR, Antigen) | 85.47% |
| Patients Tested Positive for COVID-19, Virus Detection (PCR, Antigen)1 | 147 |
| Racial and/or Ethnic Minority Patients Tested Positive for COVID-19, Virus Detection (PCR, Antigen) | 87.12% |
Patients by Race and Ethnicity
| Race/Ethnicity | Patients Tested, Virus Detection (PCR, Antigen)2 | Patients Tested Positive, Virus Detection (PCR, Antigen)2 |
|---|---|---|
| White, Non-Hispanic/Latino Patients | 10.82% | 11.56% |
| White, Hispanic/Latino Patients | 20.84% | 29.25% |
| Black/African American, Non-Hispanic/Latino Patients | 32.63% | 38.10% |
| Black/African American, Hispanic/Latino Patients | 1.29% | 0.68% |
| Asian Patients3 | 1.13% | 0.00% |
| American Indian/Alaska Native Patients3 | 0.65% | 0.68% |
| Native Hawaiian/Other Pacific Islander Patients3 | 0.32% | 0.00% |
| Patients with More Than One Race3 | 1.29% | 2.04% |
| Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 5.49% | 7.48% |
| Non-Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 1.94% | 2.72% |
| Unreported/Refused to Report Race and Ethnicity | 23.59% | 7.48% |
Patients Vaccinated
| Metrics | Value |
|---|---|
| COVID-19 Immunization Series Initiated | 447 |
| Racial and/or Ethnic Minority Patients Who Initiated COVID-19 Immunization | 78.52% |
| COVID-19 Immunization Series Completed | 313 |
| Racial and/or Ethnic Minority Patients Who Completed COVID-19 Immunization | 77.82% |
| COVID-19 Immunization Series Additional | 830 |
| Racial and/or Ethnic Minority Patients Who Received an Additional Dose of COVID-19 Vaccine | 71.39% |
Vaccinations by Race and Ethnicity
| Race/Ethnicity | Patient COVID-19 Immunization Series Initiated2 | Patient COVID-19 Immunization Series Completed2 | Patient COVID-19 Immunization Series Additional2 |
|---|---|---|---|
| White, Non-Hispanic/Latino Patients | 20.13% | 19.49% | 24.10% |
| White, Hispanic/Latino Patients | 46.09% | 37.38% | 39.64% |
| Black/African American, Non-Hispanic/Latino Patients | 1.79% | 5.11% | 1.57% |
| Black/African American, Hispanic/Latino Patients | 1.79% | 0.96% | 2.41% |
| Asian Patients3 | 0.00% | 0.00% | 0.12% |
| American Indian/Alaska Native Patients3 | 3.58% | 3.83% | 2.29% |
| Native Hawaiian/Other Pacific Islander Patients3 | 1.79% | 0.00% | 0.00% |
| Patients with More Than One Race3 | 10.74% | 5.43% | 8.31% |
| Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 7.83% | 15.65% | 5.78% |
| Non-Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 0.67% | 9.27% | 1.20% |
| Unreported/Refused to Report Race and Ethnicity | 5.59% | 2.88% | 14.58% |
Testing Logistics
Average Turnaround Time for COVID-19 Test Results, Virus Detection (PCR, Antigen)
| Metrics | Value |
|---|---|
| Less Than 1 Hour | 0.00% |
| 1 to 24 Hours | 33.33% |
| More Than 24 Hours | 66.67% |
| N/A | 0.00% |
Vaccine Logistics
Challenges in Deploying the COVID Vaccine
| Metrics | Value |
|---|---|
| Financial reimbursement for costs associated with vaccine administration | 0.00% |
| Staffing to administer the vaccine | 66.67% |
| Vaccine confidence | 66.67% |
| Vaccine storage capacity | 0.00% |
| Vaccine supply | 0.00% |
| Other | 0.00% |
| None | 0.00% |
Operations and Staff
| Metrics | Value |
|---|---|
| COVID-19 Vaccine Doses Received Only From Health Center COVID-19 Vaccine Program | 33.33% |
| Average Percent of Health Center Visits Conducted Virtually | 40.00% |
Mobile Vans, Pop-Up Clinics, and School-Based Sites
| Metrics | Value |
|---|---|
| Percent of Health Centers Hosting Mobile Vans, Pop-Up, and/or School-Based Clinics | 66.67% |
| Number of Mobile Van Sites | 0 |
| Number of Pop-up Clinics | 3 |
| Number of School-Based Vaccination Sites | 0 |
| Number of Family Vaccination Clinics | 10 |
Monoclonal Antibody Therapy
Methods in Providing Access to Monoclonal Antibody Therapy
| Metrics | Value |
|---|---|
| Direct provision of monoclonal antibody therapies | 0.00% |
| Refer patients to another organization that provides monoclonal antibody therapies | 66.67% |
| None | 33.33% |
Challenges in Providing Access to Monoclonal Antibody Therapy
| Metrics | Value |
|---|---|
| Access to therapeutics | 33.33% |
| Patient awareness/education | 33.33% |
| Staffing capacity | 33.33% |
| Therapy administration/onsite logistics | 33.33% |
| Other | 0.00% |
| None | 66.67% |
Test Kit Distribution
| Metrics | Value |
|---|---|
| Number of Health Centers that Distributed Test Kits Received through the HRSA COVID-19 Testing Supply Program | 1 |
| Number of Test Kits Distributed through the HRSA COVID-19 Testing Supply Program | 78 |
Test Kit Distribution Methods4
| Metrics | Value |
|---|---|
| Provide to Existing Health Center Patients | 100.00% |
| Provide to General Public Who Came to the Health Center | 100.00% |
| Provide at Special Vaccination Events (e.g., through mobile vans, pop-up clinics, school-based clinics, family vaccination clinics) | 0.00% |
| Provide at Other Community Events | 0.00% |
| Provide through direct outreach to specific populations (i.e., individuals experiencing homelessness, MSAWs, residents of public housing, individuals with limited English proficiency) | 0.00% |
| Other | 0.00% |
Oral Antiviral Medication Distribution
| Metrics | Value |
|---|---|
| Number of Health Centers that Provided COVID-19 Oral Antiviral Medication through the HRSA Health Center COVID-19 Therapeutics Program | 0 |
| Racial and/or Ethnic Minority Patients Who Received COVID-19 Oral Antiviral Medication5 | - |
Oral Antiviral Medication Distribution by Race and Ethnicity5
| Race/Ethnicity | Value |
|---|---|
| White, Non-Hispanic/Latino Patients | - |
| White, Hispanic/Latino Patients | - |
| Black/African American, Non-Hispanic/Latino Patients | - |
| Black/African American, Hispanic/Latino Patients | - |
| Asian Patients3 | - |
| American Indian/Alaska Native Patients3 | - |
| Native Hawaiian/Other Pacific Islander Patients3 | - |
| Patients with More Than One Race3 | - |
| Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | - |
| Non-Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | - |
| Unreported/Refused to Report Race and Ethnicity | - |
Oral Antiviral Medication Distribution by Special/Vulnerable Population5
| Metrics | Value |
|---|---|
| Migratory/Agricultural Workers | - |
| Patients Experiencing Homelessness | - |
| Patients Who Are Residents of Public Housing | - |
| Patients with Limited English Proficiency | - |
| Children Under 18 Years of Age | - |
1 The reported number of patients tested do not represent the same patients included in the reported number of patients tested positive due to a lag between the date the specimen is collected and the availability of test results. Positivity rates cannot be inferred by dividing patients tested positive by patients tested for this reason.
2 Percentages may not add to 100% due to rounding to the hundredths.
3 Includes Hispanic/Latino and Non-Hispanic/Latino.
4 Percentages are calculated using the number of health centers that have distributed test kits received through the HRSA COVID-19 Testing Supply Program as the denominator.
5 Percentages are calculated using the number of health centers that have distributed courses of COVID-19 oral antiviral medication received through the HRSA Health Center COVID-19 Therapeutics Program as the denominator.
